GREENVILLE, N.C. (WNCT) — The American College of Radiology (ACR), Breast Cancer Research Foundation (BCRF) and GE HealthCare announce the enrollment of the first patients in the Contrast-Enhanced Mammography Imaging Screening Trial (CMIST). This is a significant milestone for the clinical trial that will help determine whether contrast-enhanced mammography (CEM) improves breast cancer detection and reduces false-positive exams in women with dense breasts.

Breast cancer is currently the most commonly diagnosed cancer among American women – with
about one in eight facing a diagnosis in their lifetime. While mammography is considered the
standard breast cancer screening tool, its effectiveness is reduced in women with dense breast
tissue. Dense breast tissue is a lesser-known risk factor that can double one’s risk for breast
cancer and will soon require patient notification in the United States as a result of updates to
the Mammography Quality Standards Act (MQSA ) announced by the U.S. Food and Drug
Administration. While dense breast tissue is considered common, with about 40 percent of
women aged 40 and older having dense breasts, it can make the detection of breast cancer more challenging. For some patients, tissues can overlap potentially hiding signs of breast cancer; in other cases, the tissue and cancer can show up as white on a mammogram making diagnosis more difficult. As a result, patients often need to seek supplementary screening.

CEM combines mammography and iodinated contrast media in a simple and quick procedure to
highlight areas of unusual blood flow patterns that may indicate malignancy. The CMIST study
seeks to determine if CEM provides more accurate cancer detection compared to digital breast
tomosynthesis (DBT), or 3D mammography, in women with dense breasts. As part of CMIST, a
total of 2032 women with dense breasts will be enrolled to compare the CEM technique to 3D

Carolina Breast Imaging Specialists (CBIS) in Greenville, North Carolina is the first of fifteen
planned sites to start recruiting patients, with additional sites across the United States and
Canada commencing recruitment in the coming months. The trial is set to deliver the first results
in 2025. The trial is registered on under NCT05625659.

“We are very proud and excited to have enrolled the first patients in the multi-center CMIST trial,” said Dr. Bruce Schroeder – Medical Director and CEO of Carolina Breast Imaging Specialists. “Our patients have been eager to participate in this landmark trial both for its potential to find the earliest cancers and for its role in providing much needed data to our global knowledge base. We expect this long-awaited study to show us the value of finally having a highly effective, low-cost examination for women with dense breasts and other challenging circumstances.”

“I am extremely excited about this landmark clinical trial,” said Christopher Comstock, MD, FACR,
FSBI, CMIST Study Chair. “Despite incremental improvements in mammographic technique over
the past 50 years, screening mammography may still not detect many lethal breast cancers,
especially in women with dense breasts. This trial will help us to determine whether CEM can find
many cancers that would otherwise be missed on screening mammography and help to usher in a new screening paradigm.”

“Dense breast tissue is not only a risk factor, but also makes it increasingly difficult to identify
breast cancer. The FDA’s recent announcement requiring a single national “dense breast”
reporting standard after years of advocacy is a win for patients, as well as providers, in the fight
against breast cancer,” said Jyoti Gupta, PhD – President & CEO for Women’s Health and X-ray at
GE HealthCare. “Providing women with this information offers the potential for early diagnosis
and empowers women with dense breasts to make informed and personalized decisions about
their breast health through supplemental imaging, like contrast-enhanced mammography. I’m
excited to see our Senographe Pristina mammography system, SenoBright HD CEM technology
and contrast media from our Pharmaceutical Diagnostics segment being used to further evaluate the clinical benefits of CEM as part of our efforts to improve breast cancer outcomes.”